What is LUNG's current stock price?

LUNG (Pulmonx Corporation) is currently trading at $1.55 with a market cap of $65.5M.

What sector is Pulmonx Corporation in?

Pulmonx Corporation (LUNG) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is LUNG a good stock to buy?

Analysts have a Buy consensus on LUNG with a price target of $10.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

LUNG Pulmonx Corporation

Healthcare

$1.55+0.65%ClosedMarket Cap: $65.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.42

P/S

0.74

EV/EBITDA

-1.22

DCF Value

$-13.94

FCF Yield

-45.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

75.5%

Operating Margin

-58.8%

Net Margin

-60.1%

ROE

-92.9%

ROA

-44.4%

ROIC

-50.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$20.6M	$-13.7M	$—
Q4 null	$22.6M	$-10.4M	$—
FY null	$90.5M	$-54.0M	$—
Q3 null	$21.5M	$-14.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$9.75

Target Range

$2.50 - $20.00

0 Strong Buy4 Buy2 Hold0 Sell0 Strong Sell

D. Boral CapitalBuy

2026-04-30

Canaccord GenuityBuy

2026-03-05

D. Boral CapitalBuy

2026-03-05

D. Boral CapitalBuy

2025-11-13

Lake StreetBuy

2025-10-28

Trading Activity

Insider Trades

View All

Rose Geoffrey Beranofficer: CHIEF COMMERCIAL OFFICER

SellWed Mar 04

Rose Geoffrey Beranofficer: CHIEF COMMERCIAL OFFICER

SellWed Mar 04

Radhakrishnan Srikanthofficer: Chief Science &Techn. Officer

SellWed Mar 04

Radhakrishnan Srikanthofficer: Chief Science &Techn. Officer

SellWed Mar 04

Radhakrishnan Srikanthofficer: Chief Science &Techn. Officer

SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

0.18

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Peers